{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:37:06Z","timestamp":1792784226098,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T00:00:00Z","timestamp":1569974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"uniQure biopharma B.V."}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy - Methods & Clinical Development"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.omtm.2019.09.010","type":"journal-article","created":{"date-parts":[[2019,10,4]],"date-time":"2019-10-04T19:06:22Z","timestamp":1570215982000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes"],"prefix":"10.1016","volume":"15","author":[{"given":"Sonay","family":"Keskin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia C.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sogorb-Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raygene","family":"Martier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josse A.","family":"Depla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Vall\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander J.","family":"van Deventer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlina","family":"Konstantinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2019.09.010_bib1","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000443738","article-title":"The prevalence of Huntington\u2019s disease","volume":"46","author":"Rawlins","year":"2016","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.omtm.2019.09.010_bib2","series-title":"GeneReviews [Internet]","article-title":"Huntington disease","author":"Caron, N.S","year":"1998"},{"key":"10.1016\/j.omtm.2019.09.010_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuron.2016.02.003","article-title":"The biology of huntingtin","volume":"89","author":"Saudou","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2019.09.010_bib4","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1038\/mtna.2016.7","article-title":"Design, characterization, and lead selection of therapeutic miRNAs targeting huntingtin for development of gene therapy for Huntington\u2019s disease","volume":"5","author":"Miniarikova","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2019.09.010_bib5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/gt.2017.71","article-title":"AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington\u2019s disease","volume":"24","author":"Miniarikova","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.09.010_bib6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/gt.2017.14","article-title":"MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain","volume":"24","author":"Samaranch","year":"2017","journal-title":"Gene Ther."},{"key":"10.1016\/j.omtm.2019.09.010_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtm.2019.03.002","article-title":"AAV5-miHTT Gene Therapy Demonstrates Sustained Huntingtin Lowering and Functional Improvement in Huntington Disease Mouse Models","volume":"16","author":"Spronck","year":"2019","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omtm.2019.09.010_bib8","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington\u2019s disease minipig model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2019.09.010_bib9","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nbt.1529","article-title":"Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling","volume":"27","author":"Chambers","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2019.09.010_bib10","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nature09092","article-title":"A dicer-independent miRNA biogenesis pathway that requires Ago catalysis","volume":"465","author":"Cheloufi","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.09.010_bib11","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1126\/science.1190809","article-title":"A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity","volume":"328","author":"Cifuentes","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.omtm.2019.09.010_bib12","doi-asserted-by":"crossref","first-page":"10369","DOI":"10.1093\/nar\/gkx779","article-title":"Dicer-independent processing of small RNA duplexes: mechanistic insights and applications","volume":"45","author":"Herrera-Carrillo","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.09.010_bib13","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.celrep.2013.09.029","article-title":"Poly(A)-specific ribonuclease mediates 3\u2032-end trimming of Argonaute2-cleaved precursor microRNAs","volume":"5","author":"Yoda","year":"2013","journal-title":"Cell Rep."},{"key":"10.1016\/j.omtm.2019.09.010_bib14","doi-asserted-by":"crossref","first-page":"1942867","DOI":"10.1155\/2018\/1942867","article-title":"Human papillomavirus 16 oncoproteins downregulate the expression of miR-148a-3p, miR-190a-5p, and miR-199b-5p in cervical cancer","volume":"2018","author":"Han","year":"2018","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.omtm.2019.09.010_bib15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3389\/fgene.2018.00628","article-title":"MicroRNAs profiling identifies miR-125a and its target gene Wnt2 in skins of different haired rabbits","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.omtm.2019.09.010_bib16","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/nar\/gks797","article-title":"siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse","volume":"41","author":"Boudreau","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2019.09.010_bib17","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1080\/15476286.2015.1020270","article-title":"Passenger strand loading in overexpression experiments using microRNA mimics","volume":"12","author":"S\u00f8kilde","year":"2015","journal-title":"RNA Biol."},{"key":"10.1016\/j.omtm.2019.09.010_bib18","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.omtm.2019.09.010_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nbt.1543","article-title":"Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs","volume":"27","author":"Khan","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtm.2019.09.010_bib20","doi-asserted-by":"crossref","first-page":"e26213","DOI":"10.1371\/journal.pone.0026213","article-title":"Polymerase II promoter strength determines efficacy of microRNA adapted shRNAs","volume":"6","author":"Lebbink","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.omtm.2019.09.010_bib21","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.mcn.2017.12.009","article-title":"Perturbations in the p53\/miR-34a\/SIRT1 pathway in the R6\/2 Huntington\u2019s disease model","volume":"88","author":"Reynolds","year":"2018","journal-title":"Mol. Cell. Neurosci."},{"key":"10.1016\/j.omtm.2019.09.010_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/hum.2013.200","article-title":"Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington\u2019s disease","volume":"25","author":"Stanek","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2019.09.010_bib23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neuron.2016.03.016","article-title":"PIAS1 regulates mutant Huntingtin accumulation and Huntington\u2019s disease-associated phenotypes in\u00a0vivo","volume":"90","author":"Ochaba","year":"2016","journal-title":"Neuron"},{"key":"10.1016\/j.omtm.2019.09.010_bib24","doi-asserted-by":"crossref","first-page":"5868","DOI":"10.1073\/pnas.0801775105","article-title":"Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi","volume":"105","author":"McBride","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2019.09.010_bib25","series-title":"UniProtKB - Q96PE1 (AGRA2_HUMAN)","year":"2019"},{"key":"10.1016\/j.omtm.2019.09.010_bib26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","article-title":"Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial","volume":"16","author":"Tardieu","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.omtm.2019.09.010_bib27","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/JHD-170269","article-title":"Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay","volume":"6","author":"Fodale","year":"2017","journal-title":"J.\u00a0Huntingtons Dis."}],"container-title":["Molecular Therapy - Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301081?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050119301081?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:24:07Z","timestamp":1762421047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050119301081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":27,"alternative-id":["S2329050119301081"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2019.09.010","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AAV5-miHTT Lowers Huntingtin mRNA and Protein without Off-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy - Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2019.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s).","name":"copyright","label":"Copyright"}]}}